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Background: Parkinson’s disease is a common movement disorder affecting approximately 127,000 people in the
UK, with an estimated two thirds having speech-related problems. Currently there is no preferred approach to
speech and language therapy within the NHS and there is little evidence for the effectiveness of standard NHS therapy
or Lee Silverman voice treatment. This trial aims to investigate the feasibility and acceptability of randomizing people
with Parkinson’s disease-related speech or voice problems to Lee Silverman voice treatment or standard speech and
language therapy compared to a no-intervention control.
Methods/Design: The PD COMM pilot is a three arm, assessor-blinded, randomized controlled trial. Randomization will
be computer-generated with participants randomized at a ratio of 1:1:1. Participants randomized to intervention arms
will be immediately referred to the appropriate speech and language therapist. The target population are patients
with a confirmed diagnosis of idiopathic Parkinson’s disease who have problems with their speech or voice. The
Lee Silverman voice treatment intervention group will receive the standard regime of 16 sessions between 50
and 60 minutes in length over four weeks, with extra home practice. The standard speech and language therapy
intervention group will receive a dose determined by patients’ individual needs, but not exceeding eight weeks
of treatment. The control group will receive standard care with no speech and language therapy input for at least
six months post-randomization. Outcomes will be assessed at baseline (pre-randomization) and post- randomization
at three, six, and 12 months. The outcome measures include patient-reported voice measures, quality of life, resource
use, and assessor-rated speech recordings. The recruitment aim is at least 60 participants over 21 months from 11
sites, equating to at least 20 participants in each arm of the trial. This trial is ongoing and recruitment commenced in
May 2012.
Discussion: This study will provide information on the feasibility and acceptability of randomizing participants to
different speech and language therapies or control/deferred treatment. The findings relating to recruitment,
treatment compliance, outcome measures, and effect size will inform a future phase III randomized controlled trial.
Trial registration: International Standard Randomised Controlled Trial Number Register: ISRCTN75223808 registered
22 March 2012.
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Parkinson’s disease (PD) is a common movement dis-
order affecting approximately 127,000 people in the UK
alone [1]. Estimates of the prevalence of speech prob-
lems in people with PD range from between 51 and 70%
[2,3] and the impact of this is known to be great, leading
to increased physical and cognitive demands on the indi-
vidual during conversation, reduced independence, and
social withdrawal [4].
There are four main approaches to improving speech:
behavioral treatment techniques, assistive aids including
prosthetic and augmentative devices, and to a limited
extent, medication and surgical procedures [5]. Guide-
lines state that speech and language therapy (SLT) should
be made available for people with PD [6] but current
provision is low, with a patient survey reporting that just
37% had received SLT [7].
Currently, SLT provision for people with PD who
have problems with their speech or voice is based on
a ’traditional’ SLT approach tailored according to individual
patients’ needs, including: diaphragm breathing, pacing/
rate control, word-finding strategies, and voice/articulation
exercises (survey of speech and language therapists) [8].
The alternative and more recent approach is an intense
prescriptive intervention called Lee Silverman voice treat-
ment (LSVT®). The focus of LSVT® is to ‘think loud’, im-
proving phonation and vocal loudness through improved
vocal fold adduction [9]. Of the UK survey of speech and
language therapy respondents, 41% had received specialist
training for people with PD, with the most common being
LSVT® at 67% [8].
We have performed two Cochrane reviews of SLT in
PD [5,10]. The first compared the efficacy of SLT with a
placebo (no intervention) and included three random-
ized controlled trials (RCTs) with a total of 63 PD pa-
tients [5]. Ramig et al. [11] (n = 29) evaluated LSVT®,
whilst Robertson and Thomson [12] (n = 22) and Johnson
and Pring [13] (n = 12) both investigated various forms of
traditional SLT. Although improvements were reported
after therapy in all three trials, the review authors con-
cluded that due to the small number of patients exam-
ined, the low methodological quality of the trials, and the
possibility of publication bias, the efficacy of SLT could
not be confirmed or refuted [5]. The second review com-
pared SLT techniques and included six trials with a total
of 159 patients [10]. This review concluded that there
was insufficient evidence to support the use of one form
of SLT over another for PD patients [10]. Both reviews
recommended that a large, methodologically sound RCT
be conducted, with a follow-up period of at least six
months and meaningful outcome measures [5,10]. This
study aims to conduct a pilot trial to determine the feasi-
bility and inform the design of a future phase III RCT.
This pilot study will compare LSVT®, standard NationalHealth Service (NHS) SLT, and a no-intervention control
in people with PD. This pilot trial will be used to assess
acceptability, recruitment, data collection procedures,
compliance, outcome measures, and effect size.
The PD COMM pilot trial is designed as an assessor-
blinded, multicenter RCT with three parallel groups. In
line with guidance from the Medical Research Council
for trials of complex interventions [14] this pilot will:
assess the feasibility and acceptability of randomizing
people with PD with problems of speech or voice to the
LSVT® or traditional SLT interventions and to the
no-intervention control; assess information on patient
eligibility, recruitment, and retention rates; assess the
numbers of sites, number of patients that will need to be
screened, and the time required to undertake a full-scale
phase III trial; assess acceptability and adherence with
the LSVT® intervention; further define the dose and
content of traditional SLT; determine the suitability, sensi-
tivity, and correlation of the outcome measures; provide
estimates of the effects of the interventions to inform a
sample size calculation; pilot bespoke health economic
evaluation questionnaire using health resource data to test
the suitability of use in a future definitive trial; and assess
the suitability of data collection methods.
Methods/Design
The trial protocol and other trial documentation are
available on the PD COMM website and will be updated
with any modifications throughout the trial [15]. General
management of the trial (including procedures for ad-
verse events, audit, un-blinding, and data protection)
will follow the University of Birmingham Primary Care
Clinical Research and Trials Unit Standard Operating
Procedures (SOPS).
Recruitment
Recruitment will take place from 11 neurology and elderly
care NHS clinics from a mix of urban and rural areas in
the UK. The UKCRN networks will be asked to adopt the
study to support recruitment. Informed consent will be ob-
tained for all participants recruited into the study.
For a feasibility study no formal sample size calcula-
tion is required. We aim to recruit at least 60 participants
over 21 months from the 11 sites (at least 20 participants
in each arm of the trial) which will provide enough data to
inform a future phase III trial [16].
Inclusion criteria
The inclusion criteria are deliberately broad to allow the
inclusion of a wide spectrum of typical people with PD.
People with PD are eligible for this study if they: (1) have
idiopathic PD defined by the UK PDS Brain Bank Criteria
[17] and (2) report problems with speech or voice when
asked (or their carer does).
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The exclusion criteria for this study are as follows:
(1) dementia, as defined clinically by the physician,
(2) evidence of laryngeal pathology including vocal nod-
ules, a history of vocal strain, or previous laryngeal sur-
gery within their medical records or from discussions
with client, as LSVT® is not appropriate for this group
[9], (3) received SLT for PD speech or voice related prob-
lems in the past two years, based on a detectable treat-
ment effect reported at 24 months following LSVT® [18],
and (4) investigator is certain that the person with PD
will not require SLT during the first six months of the
trial.
The trial is 12 months duration, but participants ran-
domized to the no-intervention group can be referred
for therapy after 6 months (see below).
Consent and randomization
Potential participants who meet the eligibility criteria
will be initially approached in their normal outpatient
appointments. If interested, they will be given a patient
information sheet and time to consider the trial and dis-
cuss it with friends and family. A further meeting will be
arranged to answer any questions prior to informed con-
sent being taken. Following consent, participants will
complete baseline assessments prior to randomization.
Participants will be informed of their treatment alloca-
tion and, if allocated therapy, be referred for the initial
assessment. Baseline vocal assessments may be performed
after randomization but must be completed prior to the
start of therapy.
After completing the baseline questionnaires, partici-
pants will be randomized between the three groups at a
ratio of 1:1:1 via the Birmingham Clinical Trials Unit
(BCTU) telephone randomization service (Figure 1). This
secure central randomization service is available between
9 am and 5 pm weekdays and will ensure the concealment
of treatment allocation. A computer-generated random-
ization list will be used. Participants will be informed of
their treatment allocation but assessors will remain blind
to treatment allocation. If allocated to an intervention arm,
referral to the appropriate speech and language therapist
will occur immediately following randomization. All per-
sonal information obtained for the study will be held se-
curely and treated as strictly confidential.
Interventions
The interventions will be delivered in outpatient and
community settings. The setting will be dependent on
the provision of the speech and language therapy and
the needs of the individual participant. Logs summariz-
ing the intervention will be kept by the therapist and will
be used to monitor adherence and, in the case of the
standard SLT intervention, to document content.Lee Silverman voice treatment
The intervention will replicate the dose and content pre-
scribed by LSVT®, consisting of 16 sessions of between
50 and 60 minutes duration delivered over four weeks
[9,19]. Participants will also be set 5 to 10 minutes of
home practice on treatment days, and up to 30 minutes
of home practice on non-treatment days [20].
LSVT® comprises maximum effort non-speech and
speech drills. The non-speech drills include production
of sustained ‘ah’ phonation at a single pitch and pitch
glides (moving from low pitch to high pitch and vice
versa on production of sustained ‘ah’). These exercises
are for improving voice production and flexibility without
speech. The speech drills utilize a hierarchy of speech tasks
moving from single words through phrases and onto con-
versational speech. Each step in this hierarchy puts in-
creased demands on the speaker and challenges the
speaker to maintain maximal speech production.
Standard speech and language therapy
The content and dose of standard SLT is poorly defined
within the published literature. For this reason, the
standard therapy intervention will encompass all SLT
techniques that are not LSVT®. Treatment will be indi-
vidualized and may include (but will not be limited to)
any of the following: exercises targeting respiration,
phonation, articulation [12,13], behavioral strategies to
reduce prosodic abnormality [21], and the use of aug-
mentative and alternative communication (AAC) strat-
egies and therapeutic devices to improve functional
communication [22]. The dose will be determined by the
participant’s individual needs, but will not exceed eight
weeks of treatment. It is most likely to reflect the me-
dian dose reported in a survey of current UK speech and
language therapy practice for PD by Miller et al. [8] of 6
sessions averaging 45 minutes delivered over 42 days.
Control
If allocated to the control group participants with con-
tinue with their standard care and receive no SLT input
for at least six months post-randomization unless their
clinician deems it to be medically necessary. The six
month SLT exclusion time for this group was decided in
conjunction with therapists. After six months participa-
tion in the trial people in the control arm can be re-
ferred for therapy by their usual specialist through NHS
referral pathway.
Outcome measures
Data on various outcomes measures will be collected as
part of the PD COMM pilot in order to assess which
outcomes are appropriate to take forward to the phase
III RCT. These include both participant, therapist, and
carer completed questionnaires and measures. Outcome
Figure 1 Flow diagram detailing the participant pathway through the trials LSVT®, Lee Silverman Voice Treatment; SLT, Speech and
Language Therapy.
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3 months (post-randomization - to allow for any delays
in referral to therapy and the varying intervention
lengths), 6 months, and 12 months post-randomization
(to see if any benefit is maintained). Assessment will take
place at the therapy departments of participating centers
and will be conducted when the participant is ‘on’ medi-
cation (if medicated). Vocal assessment of intelligibility
of dysarthric speech (AIDS), loudness, and comprehen-
sion will be recorded and assessed by assessors masked
to the participant’s group allocation. Participant com-
pleted questionnaires will be conducted via post.
Effectiveness of communication will be measured using
the self-report Voice Handicap Index (VHI) [23]. The VHI
has previously been used as an outcome measure in an
extended LSVT® trial for PD [20]. Intelligibility will be
assessed using AIDS [24]. Participants will be digitally re-
corded speaking randomly generated words and sentences
from AIDS. These will then be transcribed by three blinded
assessors. Vocal loudness will be measured through sound
pressure level (in decibels) for a sustained vowel (’ah’)phonation, the reading of a ‘rainbow passage” (an articu-
lation exercise including all the normal sounds of spoken
English), and speaking freely during a self-chosen mono-
logue [18]. These will be audio-recorded and assessed by
a blinded assessor. A comprehensibility assessment will
be made using a picture, the ‘cookie theft’ picture from
the Boston diagnostic aphasia examination [25]. This will
be digitally recorded and assessed by three blinded asses-
sors. Quality of life (QoL) will be recorded through two
self-report measures; the PD-specific 39 point Parkinson’s
Disease Questionnaire (PDQ-39 [26] and the voice spe-
cific Voice-Related QoL scale (V-RQOL) [27]. Participa-
tion restriction related to speech and communication will
be assessed using the self-report Living with Dysarthria
questionnaire (LwD) [28]. The effect on carers will be
measured through the self-report Parkinson’s Carers’
Quality of Life Questionnaire [29]. Screening and treat-
ment logs will also be completed to collect data relating to
acceptability of the intervention and follow-up, recruitment
and retention rates, and participant adherence to treatment
allocation.
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EuroQol 5 Dimensions (EQ-5D) [30], capability meas-
urement using the ICEpop CAPability measure for Older
people (ICECAP-O) [31,32], and resource use using a
bespoke self-completion questionnaire. For time points
of assessment see Table 1.
Ethical approval and oversight
The PD COMM pilot trial has been granted National
Research Ethics Service (NRES) approval (Reference: 11/
WM/0343) and has an international standard random-
ized controlled trial number (ISRCTN75223808).
The trial also has a joint Data Management Committee
(DMC) and Trial Steering Committee (TSC) to monitor
the progress and safety of the trial and ensure the protocol
is adhered to. The joint TSC/DMC includes an independ-
ent chair and two further independent members.
Safety reporting
The SLT interventions within this pilot study are consid-
ered low risk. There may be a small increased risk of
vocal strain or abuse and this small risk will be clearly
stated in the participant information sheet. Every effort
will be made to minimize the risk of vocal strain or
abuse. Speech and language therapists are trained to
identify and rehabilitate vocal strain, so if present, the
therapists can quickly address it. No other risks are ex-
pected to arise from taking part in the study. It is therefore
reasonable to only collect targeted-treatment related ad-
verse events and serious adverse events such as vocal strain
or abuse. These will be collected on a study serious adverse
event form.Table 1 Outcome measures and assessment time points
Assessment type Completed by
B











Resource use questionnaire Participant
Parkinson’s Carers’ QoL Questionnaire Carer
Legend: Assessment of intelligibility of dysarthric speech (AIDS); Voice Handicap Ind
(V-RQOL); Living with Dysarthria questionnaire (LwD); EuroQol 5 Dimensions (EQ-5DAnalysis
Feasibility and acceptability
Data from screening logs completed by each centre will
provide information on the participant screening process
and will be analyzed descriptively. Reasons for non-entry
into the trial will also be assessed, particularly in relation
to the patient eligibility criteria and reasons for patient
refusal.
Data on patients who do not complete the trial (such as
withdrawals and those lost to follow-up) will also be col-
lected throughout the trial to allow assessment of patient
retention rates and reasons for non-completion of the trial.
Reasons for non-completion will be analyzed descriptively.
Adherence to SLT interventions
LSVT® is an intensive course of treatment. In this group
therapists will provide information on the mean number
and duration of sessions each patient receives during the
study in order to assess patient and therapist compliance
with LSVT®. Patients will also be asked to document
SLT homework in diaries.
Therapists administering standard NHS SLT will also
be logging information on the SLT sessions providing in-
formation on number and duration of sessions and the
type of therapy provided. This will give some insight into
the content and fidelity of standard NHS SLT, with the
mean number and duration of sessions presented, along
with a descriptive analysis of the SLT content.
Outcome data
Data from this pilot study will also be used to inform
the choice of outcome measures, provide data to informTime of administration






✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
✓ ✓ ✓
✓ ✓ ✓ ✓
ex (VHI); Parkinson’s Disease Questionnaire (PDQ-39); Voice-Related QoL scale
); ICEpop CAPability measure for Older people (ICECAP-O).
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evaluation for the full-scale trial.
Data return rates at each time point will be assessed
along with data completeness of the various outcomes
measures. The outcome data collected will be summa-
rized using descriptive statistics and an exploratory ana-
lysis will be performed. Analyses will be performed using
intention-to-treat. Data at each time point for each arm
will be presented as means with standard deviations.
The differences between the arms (LSVT® versus no
intervention, NHS SLT versus no intervention, and
LSVT® versus standard NHS SLT) in the means and
mean change from baseline to 3, 6, and 12 months will
be calculated, along with the 95% confidence intervals.
This will help to determine the sensitivity of the outcome
measures to change. Appropriate techniques (such as
correlation methods) will be used to identify which out-
come measures are closely related, which will then in-
form which outcome measures to take forward for use in
a full-scale phase III trial. The data collected within this
pilot study (estimate of the variability and treatment ef-
fect size) will help inform a sample size calculation for a
full-scale trial.
Health economics
The trial will pilot the tools to measure resource use and
outcomes that may be used in a full economic evaluation
alongside a larger trial. The rates of completion and sen-
sitivity to change will be determined.
Discussion
Speech and language therapy is an important component
of treatment for people with PD. Two recent Cochrane
reviews have concluded that evidence for the efficacy of
SLT and different SLT techniques is lacking and there-
fore well-designed RCTs are needed to address this issue
[5,10]. This trial will provide important information re-
lating to the feasibility of a definitive RCT of the effect
of SLT and LSVT® in people with PD. All aspects of
this trial will be scrutinized including the recruitment
methods, data collection procedures, outcome measures,
follow-up time points, and intervention adherence in
clinical and home settings. This pilot study is a well-
designed, rigorous RCT which is the largest in the field
to date. It has many strengths including robust blinding
and detailed approaches to the measurement and evalu-
ation of speech, and will capture previously unconsid-
ered information on adherence to home-based tasks.
As this is a pilot trial, effectiveness will not be estab-
lished. However, the data collected will be of vital im-
portance to future clinical research and necessary to
inform a phase III RCT to test the clinical and cost-
effectiveness of SLT and LSVT® on speech problems in
people with PD.Trial status
The PD COMM pilot trial is ongoing and has not com-
pleted participant recruitment which began May 2012.
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